Acadian Asset Management LLC Nektar Therapeutics Transaction History

Acadian Asset Management LLC

$28.7 Billion
Q1 2024

A detailed history of Acadian Asset Management LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Acadian Asset Management LLC holds 7,569,063 shares of NKTR stock, worth $9.39 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

7,569,063

Previous 7,818,804 3.19%

Holding current value

$9.39 Million

Previous $4.42 Million 60.06%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.49 - $0.96 $122,373 - $239,751	-249,741 Reduced 3.19%	7,569,063 $7.07 Million
Q4 2023 Feb 13, 2024	BUY	$0.42 - $0.57 $80,814 - $109,677	192,416 Added 2.52%	7,818,804 $4.42 Million
Q3 2023 Nov 13, 2023	BUY	$0.51 - $1.05 $1.65 Million - $3.39 Million	3,230,368 Added 73.48%	7,626,388 $4.54 Million
Q2 2023 Aug 07, 2023	BUY	$0.53 - $1.03 $2 Million - $3.88 Million	3,765,771 Added 597.51%	4,396,020 $2.53 Million
Q1 2023 May 11, 2023	BUY	$0.64 - $3.15 $388,456 - $1.91 Million	606,963 Added 2606.56%	630,249 $442,000

Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $47,270 - $99,664	23,286 New	23,286 $52,000
Q3 2019 Nov 07, 2019	SELL	$16.91 - $36.27 $5.39 Million - $11.6 Million	-319,029 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$31.0 - $36.3 $6.34 Million - $7.42 Million	204,394 Added 178.3%	319,029 $11.4 Million
Q1 2019 May 09, 2019	BUY	$31.58 - $46.35 $3.5 Million - $5.14 Million	110,958 Added 3017.62%	114,635 $3.85 Million
Q4 2018 Feb 07, 2019	SELL	$30.43 - $56.65 $210,301 - $391,508	-6,911 Reduced 65.27%	3,677 $121,000
Q3 2018 Oct 30, 2018	BUY	$46.46 - $68.49 $491,918 - $725,172	10,588 New	10,588 $646,000

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Nektar Therapeutics Transaction History